Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1 TR000445)
Received: 20 February 2021
Accepted: 10 March 2021
First Online: 19 March 2021
: SRR has grant support from the Canadian Institutes of Health Research (Ottawa, Canada) and Dysautonomia International (East Moriches, NY, USA). SRR is a consultant for Lundbeck LLC and Theravance Biopharma, and serves as DSMB chair for a phase 2 study run by Arena Pharmaceuticals. SRR has received compensation for editorial activities (Associate Editor) with <i>Autonomic Neuroscience—Basic and Clinical</i>. ACA: Consultant for National Vaccine Injury Compensation Program, U.S. Department of Health and Human Services; research grant from Dysautonomia International. AB: None. VEC: Research grants from the Heart and Stroke Foundation of Canada, Craig H Nielsen Foundation, and International Collaboration on Repair Discoveries. JKL: None. MN: None. VEML: None. AP: None. HS: None. SV: SV has received research support from Biohaven, Dysautonomia International, Genentech, Grifols, Rex Griswold Foundation, and Athena/Quest Diagnostics (through a licensing contract) and personal compensation for consulting for Catalyst, Sage and Alterity.
Free to read: This content has been made available to all.